MRI criteria for MS in patients with clinically isolated syndromes

Montalbán, Xavier; Tintoré, Mar; Swanton, JK; Barkhof, Frederik; Fazekas, Franz; Filippi, Massimo; Frederiksen, Jette Lautrup; Kappos, Ludwig; Palace, Jacqueline; Polman, C.H.; Rovaris, Marco; Stefano, Nicola De; Thompson, Alan J.; Yousry, Tarek; Rovira, Àlex; Miller, DH

doi:10.1212/wnl.0b013e3181cec45c

Cited by 226 publications

(153 citation statements)

References 32 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…This revised version increased the sensitivity of the critieria and simplified the features of both DIS and DIT, while maintaining the specifi city of the earlier 2001 and 2005 versions of the criteria (Table 1). 7,[11][12][13][14] The benefits of the 2010 McDonald MRI criteria included the focus on lesion location rather than lesion count, which facilitates MRI interpretation; the elimination of a mandatory interval between the clinical attack and baseline reference scan (which had been arbitrarily determined), thereby facilitating management of patients; and the acceptance of the concomitant presence of gadolinium-enhancing and gadolinium-nonenhancing lesions as evidence for DIT, which allows very early diagnosis in some patients who undergo a single MRI examination at any time after symptom onset.…”

Section: Discussionmentioning

confidence: 99%

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

et al. 2015

View full text Add to dashboard Cite

| The clinical use of MRI in patients with multiple sclerosis (MS) has advanced markedly over the past few years. Technical improvements and continuously emerging data from clinical trials and observational studies have contributed to the enhanced performance of this tool for achieving a prompt diagnosis in patients with MS. The aim of this article is to provide guidelines for the implementation of MRI of the brain and spinal cord in the diagnosis of patients who are suspected of having MS. These guidelines are based on an extensive review of the recent literature, as well as on the personal experience of the members of the MAGNIMS (Magnetic Resonance Imaging in MS) network. We address the indications, timing, coverage, reporting and interpretation of MRI studies in patients with suspected MS. Our recommendations are intended to help radiologists and neurologists standardize and optimize the use of MRI in clinical practice for the diagnosis of MS.

show abstract

Section: Discussionmentioning

confidence: 99%

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

et al. 2015

View full text Add to dashboard Cite

show abstract

“…34 Subjects self-reported of being of European descent. Each individual signed the informed consent document approved by the Institutional Review Board of Partners Healthcare.…”

Section: Study Participantsmentioning

confidence: 99%

HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study

et al. 2010

View full text Add to dashboard Cite

Several major histocompatibility complex (MHC) alleles have been postulated to influence the susceptibility to multiple sclerosis (MS), as well as its clinical/radiological course. In this longitudinal observation, we further explored the impact of human leukocyte antigen (HLA) class I/II alleles on MS outcomes, and we tested the hypothesis that HLA DRB1*1501 might uncover different strata of MS subjects harboring distinct MHC allele associations with magnetic resonance imaging (MRI) measures. Five hundred eighteen MS patients with two-digit HLA typing and at least one brain MRI were recruited for the study. T2-weighted hyperintense lesion volume (T2LV) and brain parenchymal fraction (BPF) were acquired at each time point. The association between allele count and MRI values was determined using linear regression modeling controlling for age, disease duration and gender. Analyses were also stratified by the presence/absence of HLA DRB1*1501. HLA DRB1*04 was associated with higher T2LV (P ¼ 0.006); after stratification, its significance remained only in the presence of HLA DRB1*1501 (P ¼ 0.012). The negative effect of HLA DRB1*14 on T2LV was exerted in DRB1*1501-negative group (P ¼ 0.012). Longitudinal analysis showed that HLA DRB1*10 was significantly protective on T2LV accrual in the presence of HLA DRB1*1501 (P ¼ 0.002). Although the majority of our results did not withstand multiple comparison correction, the differential impact of several HLA alleles in the presence/absence of HLA DRB1*1501 suggests that they may interact in determining the different phenotypic expressions of MS.

show abstract

“…3,[5][6][7] In the clinical setting, it is highly relevant that GM abnormalities in MS can be visualized in vivo: first, because GM abnormalities strongly explain cognitive and physical disability, 8,9 and second, because focal GM lesions are rather specific for MS. They already occur in the earliest stages of the disease, 10,11 and it was suggested that the McDonald criteria for the diagnosis of MS-at present completely based on WM lesion detection 1,12 -will be of increased accuracy when cortical GM lesions are included. 13 Due to a higher SNR with increased spatial resolution, MS lesion detection has improved by moving from 1.5T MR imaging to 3T.…”

mentioning

confidence: 99%

Multicontrast MR Imaging at 7T in Multiple Sclerosis: Highest Lesion Detection in Cortical Gray Matter with 3D-FLAIR

Kilsdonk¹,

Graaf²,

Soriano³

et al. 2012

AJNR Am J Neuroradiol

Self Cite

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:7T MR imaging has led to improved detection and classification of cortical MS lesions, mainly based on T2*-weighted gradient-echo sequences. Depiction of cortical GM by using the recommended MS imaging protocol has not yet been investigated at 7T. We aimed to investigate prospectively which recommended sequence for clinical use has the highest value at 7T, in terms of GM and WM lesion detection.

show abstract

MRI criteria for MS in patients with clinically isolated syndromes

Cited by 226 publications

References 32 publications

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study

Multicontrast MR Imaging at 7T in Multiple Sclerosis: Highest Lesion Detection in Cortical Gray Matter with 3D-FLAIR

Contact Info

Product

Resources

About